Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Aleksandar
Contact Aleksandar, search articles and posts on X, monitor coverage, and track replies from one place.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Abstract Intratumor heterogeneity fundamentally challenges cancer treatment, as coexisting, molecularly distinct cell states with non-overlapping drug sensitivities can drive therapeutic resistance. We establish and validate a generalizable, network-based framework to systematically identify combination therapies targeting complementary tumor cell states.
ArticleVolume 7, Issue 3102638Open access Affiliations & Notes 1Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, 10032, United States of America 2Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY, 10032, United States of America 3Department of Immunology, Mayo Clinic Arizona, Phoenix, AZ, 85054, United States of America 4Department of Urology, Mayo Clinic Arizona, Phoenix,...
Keywords regulatory T cells CTLA-4 prostate cancer neoadjuvant immunotherapy CyTOF single-cell RNA sequencing tumor-associated macrophages dendritic cells Introduction To date, immune checkpoint blockade immunotherapy (ICB) has proven largely ineffective for patients with prostate cancer (PCa).1,2,3 Agents targeting the PD-1/PD-L1 pathway alone or in combination with androgen receptor inhibitors,4,5,6 chemotherapy,7 or PARP inhibition8 have failed in phase III trials.9 Similarly, CTLA-4...
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
